Table 1. Patient characteristics (mean values are displayed).
| Number | Age (years) | Gender | ASA score | MELD score | Primary tumor | Ki-67 primary tumor | Treatment prior to RE | Hepatic tumor load | Ki-67 liver metastasis | Radioembolization | RE dose (MBq) | Time from RE to surgery (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 53.8 | M | 2 | 6 | pNET | 20 | PRRT, SSA, TACE | 60 | 50 | Whole liver | 2,200 | 26.3 |
| 2 | 55.2 | M | 3 | 6 | pNET | 5 | SSA | 1 | 4 | Whole liver | 2,069 | 95.2 |
| 3 | 59.5 | M | 2 | 6 | siNET | 3 | SSA | 10 | 3 | Whole liver | 1,406 | 4.7 |
| 4 | 63.9 | F | 3 | 12 | siNET | 5 | SSA | 60 | 12 | Whole liver | 1,708 | 20.9 |
| 5 | 59.3 | F | 3 | 8 | siNET | 1 | SSA | 30 | 1 | Whole liver | 1,696 | 10.9 |
| 6 | 60.2 | F | 3 | 6 | Rectum | 5 | none | 30 | 6 | Right lobe, S. IV | 1,828 | 3.1 |
| 7 | 59.0 | M | 3 | 6 | siNET | 5 | SSA | 30 | 5 | Whole liver | 1,754 | 3.3 |
| 8 | 75.0 | F | 3 | 9 | siNET | 3 | PRRT | 30 | 8 | Whole liver | 1,310 | 52.3 |
ASA, American Society of Anesthesiologists; F, female; M, male; MELD, Model of End Stage Liver Disease; n/a, not applicable; pNET, pancreatic neuroendocrine tumor; PRRT, peptide receptor radionuclide therapy; RE, radioembolization; SSA, somatostatin analogs; siNET, small intestine neuroendocrine tumor; TACE, transarterial chemoembolization.